LevodopaAn immediate precursor of dopamine and product of tyrosine hydroxylase

Levodopa (CAS 59-92-7)

Levodopa | CAS 59-92-7 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_15, h_7
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205372, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 36ms
  • REVIEWS, PRODUCT
Synonym: L-DOPA; 3,4-Dihydroxyphenylalanine
Application: An immediate precursor of dopamine and product of tyrosine hydroxylase
CAS Number: 59-92-7
Purity: ≥98%
Molecular Weight: 197.19
Molecular Formula: C9H11NO4
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Levodopa is a natural form of DOPA used in the treatment of Parkinson's disease. Immediate precursor of dopamine and product of tyrosine hydroxylase.


References

Morris JG. Clin Exp Neurol. 15:24-50 (1978).

Appearance :
Crystalline powder
Physical State :
Solid
Solubility :
Soluble in water (66 mg/ml), DMSO (<1 mg/ml at 25° C), and 0.5M HCl (50 mg/ml). Insoluble in ethanol, and chloroform.
Storage :
Store at -20° C
Melting Point :
276-278° C (lit.)
Boiling Point :
~448.4° C at 760 mmHg (Predicted)
Density :
~1.5 g/cm3 (Predicted)
Refractive Index :
n20D ~1.66 (Predicted)
Optical Activity :
α25/D -11.5°±1°, c = 1 in hydrochloric acid
IC50 :
Fyn: IC50 = 2.15 µM (human); 15-LO: IC50 = 2.26 µM (human); EGFR: IC50 = 2.88 µM (human); Lck: IC50 = 3.73 µM (human); Tyrosinase: IC50 = 8.4 mM (human)
pK Values :
pKa: pK1: 2.3, pK2: 8.7, pK3: 9.7, pk4: 13.4, (25° C). pKb: 8.85 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
AY5600000
PubChem CID :
6047
Merck Index :
14: 5464
MDL Number :
MFCD00002598
EC Number :
200-445-2
Beilstein Registry :
2215169
SMILES :
C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 45ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Cote Cote, SR. et al. (PubMed 25445374) reported that chronic Levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease. -SCBT Publication Review
Date published: 2015-04-27
  • y_2019, m_9, d_15, h_7
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205372, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 104ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.